Bioequivalence and Bioavailability Forum • EMEA at its best

EMEA at its best [Design Issues]

posted by drcampos – Brazil, 2009-08-24 21:26 (6151 d 01:07 ago) – Posting: # 4103
Views: 7,653

Dear Muneesh,

I conducted a bioequivalence study of rivastigmine 6mg in healthy volunteers two months ago. Ondansetron was administered to avoid nausea and vomiting.

The administration was done as follows: 4mg in 50mL (infusion of 15 minutes immediatly after the administration of the drug)

2 hours after the administration of the drug (around Cmax/Tmax): 4mg in 100mL (infusion of 30 minutes).

Regards,

Daniel Rossi de Campos
Brazil

Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

BE study of Rivastigmine 6 mg in healthy volunteers drmuneesh 2009-08-21 10:59
- Rivastigmine 6 mg: patients? Helmut 2009-08-21 23:17
  - Rivastigmine 6 mg: patients? drmuneesh 2009-08-22 06:51
    - Rivastigmine 6 mg (EU centralised procedure) Helmut 2009-08-22 13:56
    - Rivastigmine 6 mg: patients? ElMaestro 2009-08-22 17:47
      - EMEA at its best Helmut 2009-08-22 18:37
        
        EMEA at its best ElMaestro 2009-08-22 19:17
        
        EMEA at its best drmuneesh 2009-08-24 13:59
        
        EMEA at its bestdrcampos 2009-08-24 19:26
        
        EMEA at its best drmuneesh 2009-08-25 06:12
        
        Rivastigmine BE Dr Lalit 2009-08-25 14:41
        
        Rivastigmine BE drmuneesh 2009-08-26 06:29